Compare Regeneron Pharmaceuticals Inc (REGN) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs TeraWulf Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while TeraWulf Inc trades at $19.88 (market cap $9.84B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 7.2× TeraWulf Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while TeraWulf Inc pays none. Which is the better fit depends on your goals.
| REGN | WULF | |
|---|---|---|
Market Cap | $70.79B | $9.84B |
Sector | Health | Technology |
52-Week High | $812.27 | $28.98 |
52-Week Low | $545.46 | $4.76 |
Enterprise Value | $64.74B | $12.53B |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
TeraWulf (WULF) trades at $18.86, up 3.85% today, amid volatile AI infrastructure sector movements. The stock shows bearish technical signals with negative earnings trends, having missed Q1-Q3 2025-2026 EPS estimates. Fundamentally, the company reported a net loss of $661.42M on $168.46M revenue in 2025, though it secured a significant 20-year, $19B deal with Anthropic for AI data center capacity.
Despite unanimous analyst buy ratings and a $37.22 consensus price target suggesting 97% upside, WULF faces execution risks from high cash burn and negative margins. The Anthropic partnership offers long-term revenue potential but requires substantial capital investment amid competitive and regulatory pressures in the AI infrastructure space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
